Last €9.40 EUR
Change Today -0.13 / -1.36%
Volume 20.5K
ALCLS On Other Exchanges
EN Paris
As of 11:35 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/14 - €14.58
52 Week Low
12/17/13 - €2.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company’s products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.

193 Employees
Last Reported Date: 04/30/14
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cellectis (ALCLS) Key Developments

Cellectis SA Reports Consolidated Earnings Results for the First Half Ended June 30, 2014

Cellectis SA reported consolidated earnings results for the first half ended June 30, 2014. For the period, the company reported total operating revenue is EUR 13.8 million as compared to EUR 6.9 million for the first six months of 2013, i.e. an increase of 100%. Total operating revenue does not include revenue arising from the agreement signed with Pfizer, which will come into effect only from the second half of 2014. Operating results are notably improved, with losses limited to EUR 2.1 million as compared to EUR 16.5 million for the first six months of 2013. Net results show a loss of EUR 5 million, which is in sharp contrast to the loss recorded for the first half of 2013, which amounted to EUR 18.5 million.

Cellectis, Board Meeting, Sep 29, 2014

Cellectis, Board Meeting, Sep 29, 2014. Agenda: To approve the first-half 2014 consolidated financial statements.

Cellectis Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 02:45 PM

Cellectis Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 02:45 PM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Speakers: André Choulika, Founder, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €9.40 EUR -0.13

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellular Dynamics International Inc $6.94 USD -0.0983
General Electric Co $24.95 USD +0.13
Lonza Group AG SFr.106.90 CHF +0.90
Sigma-Aldrich Corp $134.54 USD +0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.6x
Price/Book 9.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at